|
The importance of evaluating long term responder fraction using complementary statistical approaches in immune checkpoint inhibitors phase III trials: An in-silico study using keynote 045 study. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Merck |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; Pfizer; Sanofi |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen |
Speakers' Bureau - Janssen; Takeda |
Research Funding - Astellas Pharma (Inst) |
Travel, Accommodations, Expenses - Ipsen; Janssen |
|
|
Consulting or Advisory Role - MSD Oncology; Novartis; Roche/Genentech; Roche/Genentech |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst) |
|
|
Consulting or Advisory Role - Cellectis (Inst) |
Research Funding - Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst) |